Who We Work With
We represent late-stage biotech and medical device companies at the inflection point between validated science and commercial launch. Companies that have exhausted early-stage funding and need $10 million to $50 million for clinical trials, FDA approval, or commercial launch.
We work with 3 to 5 companies at a time. Every engagement gets our full attention. We only take on companies we are prepared to stand behind personally.
What we do
We translate your science into the language institutional capital understands. We identify the right investors for your specific opportunity. We manage the process from first introduction through closing.
Our investor relationships include family offices, institutional growth equity funds, and healthcare-focused venture groups across California, Canada, Europe, and the Middle East.
Our fee structure
For companies that have exhausted their runway: pure success fee of 10% (5% cash, 5% equity at closing). No retainer.
For companies with existing capital: $10,000 monthly retainer, credited at closing, plus 10% success fee (5% cash, 5% equity).
We take equity in every engagement because we are your partner, not a transaction. We succeed when your technology reaches patients and generates returns for investors.Contact us to discuss how we can serve your healthcare investment strategy.
How to start
The first meeting is always face-to-face. If that isn’t possible, we start with a video call.
We need to meet you in person before we agree to represent you. That standard protects the integrity of every relationship in our network, including yours.